Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

SD Cystic Fibrosis Study

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00605761
First received: January 18, 2008
Last updated: March 15, 2012
Last verified: April 2011
  Purpose

Subject with Cystic Fibrosis have increased clearance of many drugs. Based on pre-clinical data SB656933 was found to have low clearance and high bio-availability. This study will characterize the PK profile of a single dose of SB656933 in patients with Cystic Fibrosis. There will be two groups of subjects. The first group of subjects will receive a single dose of 50mg SB-656933. The second group of subjects will receive a single dose of up to 300 mg SB-656933. Subjects will first be screened for eligibility related to cystic fibrosis history. Safety evaluations will be undertaken and plasma samples for pharmacokinetic analysis will be collected. Additional blood samples will be taken for the pharmacodynamic endpoints CD11b and GAFS. Subjects are not required to stay overnight after their 12 hour PK sample collection on Day 1, although they may do so if they wish. On Day 2 and 3, they will return for collection of additional safety measurements, and further plasma and blood samples will be taken for 24 and 48 h pharmacokinetics and 24h CD11b/GAFS measurements, respectively.

A follow up visit (Visit 3) will be made 4-7 days after the treatment period. Subjects will be enrolled in the study for approximately 3to 7 weeks (from screening to follow-up).


Condition Intervention Phase
Cystic Fibrosis
Drug: SB656933
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: An Open Label Dose Ascending, Single Dose Study to Investigate the Pharmacokinetics of SB-656933 in Subjects With Cystic Fibrosis.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Blood samples [ Time Frame: over a 48 hour time-period after single dosing with either 50mg or up tp 300mg SB656933 ]

Secondary Outcome Measures:
  • Safety: ECG, vital signs, clinical labs [ Time Frame: over 48hours post SB656933 dosing in both dosing sessions ]
  • Continuous adverse event monitoring [ Time Frame: from dosing until study conclusion and follow up, 4-7 days after the treatment period ]

Enrollment: 9
Study Start Date: February 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort 1
50 mg treatment
Drug: SB656933
50 mg treatment
Other Name: SB656933
Experimental: Cohort 2
150 mg treatment
Drug: SB656933
150 mg treatment

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Have Cystic Fibrosis
  • Male greater or equal to 18 years of age or female greater or equal to 16 years of age.
  • Must not be a smoker, or have smoked cigarettes or used other tobacco products regularly in the last 6 months
  • Must be clinically stable with no change in symptoms or medication, no admissions to hospital, no intravenous antibiotic therapy for at least 2 weeks before study start.
  • Able to perform lung function tests
  • Lung test reading with FEV1 >40% predicted
  • Lung test with FEV1 has not changed by >10% over past 12 months
  • Must have a normal ECG.
  • Women of child bearing potential must use an effective method of contraception.
  • Male subjects must agree to abstain from or use a condom during sexual intercourse or use a condom/spermicide, in addition to having their female partner use another form of contraception.
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) normal at study start.
  • Signed and dated written informed consent.
  • The parent/guardian must give written informed consent for the child to participate in this investigation. Adolescents must also sign the informed consent
  • The subject is able to understand and follow protocol.

Exclusion Criteria:

  • Any clinically abnormality found at screening that is not part of the disease of cystic fibrosis.
  • any problem with pancrease
  • fatty feces
  • liver problems
  • sudden weight loss or poor nutritional status.
  • high blood pressure
  • infected with the hepatitis B, hepatitis C, or HIV virus
  • History of regular alcohol use
  • a current non-smoker
  • uses corticosteroids; regular use of high dose NSAIDs, within 2 months of study start.
  • have had positive Burkholderia cepacia, or MRSA within the last 12 months
  • on treatment for any mycobacterial infection
  • cannot be withdrawn from oral azithromycin during study
  • any marked bleeding haemoptysis in the last 12 months.
  • has taken more than 4 new chemical entities within the last year.
  • donate more than 500 mL within the last 56 day.
  • taken part in a drug trial in 30 days or taken part in a trial with a new chemical within the last 2 months.
  • on drugs that are CYP3A4, CYP2B6, CYP2C8 or OATP1B1 substrates with a narrow therapeutic index are excluded.
  • using non-prescription drugs, including, herbal and dietary supplements (including St John's Wort) within 7 days or unless permitted by the Investigator and sponsor
  • Consumption of grapefruit juice in last 7 seven day before study start.
  • Pregnant or breast feeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00605761

Locations
United States, California
GSK Investigational Site
Palo Alto, California, United States, 94304
United States, Minnesota
GSK Investigational Site
Minneapolis, Minnesota, United States, 55455
United States, Pennsylvania
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00605761     History of Changes
Other Study ID Numbers: CF2110398
Study First Received: January 18, 2008
Last Updated: March 15, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
Cystic Fibrosis
Lung function
Anti-Inflammatory

Additional relevant MeSH terms:
Cystic Fibrosis
Fibrosis
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on November 19, 2014